Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, Andreas; Réa, Delphine; Boquimpani, Carla; Minami, Yosuke; E. Cortes, Jörge; P. Hughes, Timothy; F. Apperley, Jane; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong‐Wook; Abdo, André; Fogliatto, Laura; le Coutre, Philipp; Sasaki, Koji; Dong Hwan Kim, Dennis; Saußele, Susanne; Annunziata, Mario; Chaudhri, Naeem; Chee, Lynette; García‐Gutiérrez, Valentín; S. Kapoor, S.; Allepuz, Alex; Quenet, Sara; Bédoucha, Véronique; J. Mauro, Michael

doi:10.1038/s41375-023-01829-9

Public

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Published in Leukemia • Jan 30, 2023

Authors:

Andreas Hochhaus

Delphine Réa

Carla Boquimpani

Abstract

Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In ...

Subject

Bosutinib

Discontinuation

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!